News About: R&D
Investment efficiency of new drug R&D enhanced by out-sourcing
The commercialization of the first domestic new drug strongly motivated local pharmaceutical industry to seek enhancement of efficiency in new drug R&D investment by means of utilizing the third party resource in thei...
Foreigner's drug community seeks government special privilege on new drugs.
The foreign pharmaceutical corporations made a strategic approach to our government through an international diplomatic channel and American PMA for the future new drugs to get the price approval at a higher level tha...
Domestic and foreign drug firms on patent dispute.
As domestic firms are developing new drugs that could be manufactured by their patented process developed by their own research and technology resulting from the R&D progress through long time investment for their res...
Insurance price determination standards for new drugs under review.
The MOHW plans to make a Task Force for overall review of the new standards for insurance drug price determination that should be more reasonable and objective in consideration with characteristics of drugs and their ...
Whanin developed alcohol detoxicated drug for world 2nd time.
Whanin pharmaceutical company developed a manufacture of Acamprosate, an alcohol detoxicated drug under a joint research with Estech, a domestic venture company producing pharmaceutical bulk products after obtaining t...
Insurance pricing on new drugs specially privileged
The foreign multinational drug companies and local drug industries shared with common goals for the future insurance reimbursement price of new drugs to get some privileges in process of the government price determina...
Dongwha's DW166HC likely to be No. 2 new drugs in Korea.
SK pharmaceutical obtained the manufacturing licence of a platinum complex preparation as a new drug with passing through the clinical phase II studies only, which was exceptional for an anticancer drug while provisio...
Sunpla expected yearly to yeild 10 billion won of sales
As reported earlier SK Chemical and SK Pharmaceutical has developed an anti-cancer drug, a platinum complex, under the brand of Sunpla by about 8.1 billion won of investment during the past 10 years, which becomes the...
Domestic new drug No. 1, Sunpla inj. approved
The KFDA approved Sunpla inj., a platinum chelate complex anticancer drug, as the first new drug originated from Korea on July 13, which was developed by SK Pharmaceutical (President: Cho Min-ho) at 8.1 billion won of...
21 new drugs under clinical research.
Along with the first introduction of domestically developed new drug many interesting attentions are paid to the 21 candidates of new drugs in future, which are still under the clinical research stage and 2 ...
